Source: International Congress 2019 – Biology and prognosis of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
G. Sotiropoulos (Athens, Greece), M. Kotopouli (Athens, Greece), I. Karampela (Athens, Greece), G. Christodoulatos (Athens, Greece), G. Antonakos (Athens, Greece), I. Marinou (Athens, Greece), E. Vogiatzakis (Athens, Greece), A. Lekka (Athens, Greece), A. Papavassiliou (Athens, Greece), M. Dalamaga (Athens, Greece). Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers. 3058

Member's Comments

No comment yet.

Related content which might interest you: Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Hypoxia-response gene signatures as predictive and prognostic biomarkers in advanced non-squamous non-small cell lung cancer patients Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron- specific enolase in patients with advanced non-small-cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019